QGEN Stock Rises in After Market Following Partnership With Incyte

QIAGEN N.V. QGEN recently announced a new global collaboration with Incyte INCY. The partnership enhances QIAGEN’s onco-hematology diagnostics pipeline and supports Incyte’s extensive portfolio in myeloproliferative neoplasms (MPNs), including monoclonal antibody INCA033989. QGEN Stock’s Likely Trend Following the NewsFollowing the announcement yesterday, shares of QIAGEN moved up 0.1% to $47.17 in the pre-market trading session today. As part of QIAGEN’s long-term business strategy, it has forged strategic alliances as well as marketing and distribution arrangements with academic, corporate and other partners to support the development, commercialization, and distribution of existing and potential products. As a result, we expect the latest partnership to positively boost the market sentiment toward QGEN stock.QIAGEN has a market capitalization of $10.20 billion. The company’s earnings yield of 5% compares favorably to the industry average of -29.4%. In the trailing four quarters, it delivered an average earnings surprise of 4.9%. More on QIAGEN’s Collaboration With IncyteUnder the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. Further, the panel will be validated on Illumina NextSeq 550Dx platform for use with whole blood samples. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union, and Asia-Pacific regions.Importance of the CollaborationMyeloproliferative neoplasms are a group of diseases representing about 40% of hematological malignancies, characterized by chronic accumulation of different mature blood cell types in the blood. Identifying genomic aberrations in clinically relevant biomarkers like calreticulin (CALR) is shown to be key, especially in MPNs. Companion diagnostic identifies key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR, the second most common driver of MPNs. Together with Incyte, QIAGEN is building a multimodal companion diagnostic using a powerful technology like NGS to facilitate highly accurate testing for several blood cancer genes at once. This new partnership strengthens QIAGEN’s role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit. Image Source: Zacks Investment ResearchAnother Strategic Alliance by QIAGENLast month, QIAGEN inked a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality dPCR assays and customized molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications.Industry Prospects Favor QGENPer a MarketsandMarkets report, the global hemato-oncology testing market is expected to witness a CAGR of 14.2% during 2022-2027. The growth in this market is attributed to the increasing number of hematologic cancer patients, as these patients require regular monitoring and diagnostic testing during treatment. QGEN Stock Price PerformanceIn the past year, QGEN shares have risen 4.7% against the industry’s 12.7% decline. QGEN’s Zacks Rank and Other Key PicksQIAGEN currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Hims & Hers Health HIMS and Cencora COR. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Cencora carry a Zacks Rank #2 each. You can see the complete list of today’s Zacks #1 Rank stocks here.Estimates for Phibro Animal Health’s fiscal 2025 earnings per share (EPS) have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 36.2% in the past year compared with the industry’s 10.5% growth. Its earnings yield of 8.7% compares comfortably with the industry’s 0.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%.Hims & Hers Health shares have surged 176% in the past year. Estimates for the company’s 2025 EPS have jumped 12.5% to 72 cents in the past 30 days. HIMS’ earnings beat estimates in two of the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%.Estimates for Cencora’s fiscal 2025 EPS have increased 2.5% to $15.75 in the past 30 days. Shares of the company have jumped 26.4% in the past year against the industry’s 21% decline. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. In the last reported quarter, it delivered an earnings surprise of 8.3%.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis Report Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks